AB SCIENCE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.936 EUR | +2.76% |
|
-1.63% | -45.54% |
| 04-04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| 04-03 | AB Science: reconsideration possible for masitinib in ALS | CF |
| Sales 2023 * | 930K 994K 79.63M | Sales 2024 * | 990K 1.06M 84.77M | Capitalization | 98.86M 106M 8.47B |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -20.32M -1.63B | Net income 2024 * | -18M -19.25M -1.54B | EV / Sales 2023 * | 106 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 99.9 x |
| P/E ratio 2023 * |
-5.09
x | P/E ratio 2024 * |
-5.38
x | Employees | 89 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on AB Science
More press releases
More news
| 1 day | +2.76% | ||
| 1 week | -1.63% | ||
| Current month | -23.48% | ||
| 1 month | -25.68% | ||
| 3 months | -49.71% | ||
| 6 months | -13.18% | ||
| Current year | -45.54% |
1 week
1.88
2.03
1 month
1.882.61
Current year
1.554.47
1 year
1.556.54
3 years
1.5516.68
5 years
1.5521.75
10 years
1.5521.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 10/07/01 |
Laurent Guy
DFI | Director of Finance/CFO | - | 31/12/01 |
| Chief Tech/Sci/R&D Officer | - | 31/03/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 10/07/01 |
Patrick Moussy
BRD | Director/Board Member | - | 10/07/01 |
| Director/Board Member | 62 | 26/06/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.936 | +2.76% | 32,531 |
| 25/04/24 | 1.884 | -2.89% | 71,388 |
| 24/04/24 | 1.94 | -2.02% | 68,439 |
| 23/04/24 | 1.98 | -0.90% | 57,815 |
| 22/04/24 | 1.998 | +1.52% | 75,972 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotes
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.936
EUR
Average target price
6.895
EUR
Spread / Average Target
+256.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -45.54% | 106M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- AB Stock
